Belite Bio (BLTE) Total Non-Current Liabilities (2024 - 2025)
Belite Bio (BLTE) recorded quarterly Total Non-Current Liabilities of $188000.0 in Q4 2025, down 27.97% quarter-over-quarter from $261000.0 in Q4 2024, and down 27.97% on a YoY basis from $261000.0 in Q4 2024.
Belite Bio (BLTE) Total Non-Current Liabilities (2024 - 2025) Analysis & Trends
Belite Bio's Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $188000.0 for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities fell 27.97% year-over-year to $188000.0; the TTM figure through Dec 2025 stood at $188000.0 (down 27.97% YoY), while the FY2025 annual figure was $188000.0, down 27.97% from the prior year.
- Total Non-Current Liabilities was $188000.0 for Q4 2025 at Belite Bio, down from $261000.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $261000.0 in Q4 2024 to a low of $188000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 7.32 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 188,000.00 |
| Dec 31, 2024 | 261,000.00 |